for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Siemens Healthineers AG

SHLG.DE

Latest Trade

37.25EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

28.50

 - 

47.27

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
37.25
Open
--
Volume
--
3M AVG Volume
23.97
Today's High
--
Today's Low
--
52 Week High
47.27
52 Week Low
28.50
Shares Out (MIL)
1,074.35
Market Cap (MIL)
40,484.50
Forward P/E
25.05
Dividend (Yield %)
2.12

Next Event

Siemens Healthineers AG Annual Shareholders Meeting

Latest Developments

More

Siemens Healthineers Collaboration With CDC To Define Threshold For Neutralizing Antibody Sufficient To Confer Immunity

Siemens Healthineers AG Determines The Placement Price For The New Shares From The Capital Increase

Siemens Healthineers Primary ABB Bookrunner Says Books Are Covered

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Siemens Healthineers AG

Siemens Healthineers AG is a Germany-based company that supplies technology to the healthcare industry. The Company offers a wide range of products and services in the fields of diagnostic and therapeutic imaging, laboratory and point of care diagnostics, and molecular medicine. It provides medical technology and software solutions, as well as clinical consulting services. Additionally, the Company is developing its digital health and enterprise services trough expanding precision medicine, transforming care delivery, improving patient experience, and digitalizing healthcare to enable healthcare providers to increase value. Siemens AG is a majority shareholder of the Company. The Company is active worldwide.

Industry

Medical Equipment & Supplies

Contact Info

Henkestr. 127

91052

Germany

+49.69.66826602

https://www.siemens-healthineers.com/

Executive Leadership

Michael Sen

Chairman of the Supervisory Board

Bernhard Montag

President of the Management Board, Chief Executive Officer

Norbert Gaus

Vice Chairman of the Supervisory Board

Jochen Schmitz

Chief Financial Officer, Member of the Managing Board

Christoph Zindel

Member of the Managing Board

Key Stats

2.42 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2018

13.4K

2019

14.5K

2020(E)

14.7K
EPS (EUR)

2018

1.380

2019

1.570

2020(E)

1.495
Price To Earnings (TTM)
25.53
Price To Sales (TTM)
2.75
Price To Book (MRQ)
3.87
Price To Cash Flow (TTM)
17.80
Total Debt To Equity (MRQ)
5.57
LT Debt To Equity (MRQ)
2.96
Return on Investment (TTM)
9.46
Return on Equity (TTM)
6.94

Latest News

Latest News

Siemens Healthineers in advanced talks to buy Varian for $15 billion: Bloomberg News

German group Siemens Healthineers AG <SHLG.DE> is in advanced talks to purchase Varian Medical Systems Inc <VAR.N>, a maker of devices and software for treating cancer, in a deal that will value the medical device maker at about $15 billion, Bloomberg News reported late...

BRIEF-Siemens Healthineers And Geisinger Announce Partnership

* SIEMENS HEALTHINEERS AND GEISINGER ANNOUNCE VALUE PARTNERSHIP TO DRIVE DIGITAL HEALTHCARE

BRIEF-Siemens Healthineers Receives FDA Emergency Use Authorization For Its SARS-CoV-2 Total Antibody Test

* SIEMENS HEALTHINEERS RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR ITS SARS-COV-2 TOTAL ANTIBODY TEST THAT DELIVERS SUPERIOR CLINICAL PERFORMANCE

BRIEF-Siemens Healthineers To Expand SARS-COV-2 Testing

* TO EXPAND SARS-COV-2 TESTING TO INCLUDE A TOTAL ANTIBODY TEST TO AID IN COVID-19 PANDEMIC

BRIEF-Siemens Healthineers To Equip Hospitals In Bavaria For Diagnosis Of COVID-19 Patients

* STATE MINISTRY OF HEALTH AND CARE TO PURCHASE WIDE RANGE OF EQUIPMENT FOR DIAGNOSIS AND MONITORING OF COVID-19 PATIENTS

BRIEF-Siemens Healthineers - FDA Clears Rapidpoint 500E Blood Gas Analyzer Used For Critically Ill Patients In Acute Care Settings

* FDA CLEARS SIEMENS HEALTHINEERS RAPIDPOINT 500E BLOOD GAS ANALYZER USED FOR CRITICALLY ILL PATIENTS IN ACUTE CARE SETTINGS Source text for Eikon: Further company coverage:

BRIEF-Siemens Healthineers CEO Says We Have Succeeded In Keeping Our Business Stable So Far

* CEO - WE'RE WORKING ON CORONAVIRUS TEST THAT IS NOT LINKED TO A CERTAIN ANALYSIS PLATFORM

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up